TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25939066

Group type: EXPERIMENTAL
Intervention: Atypical antipsychotics (specific dosage and duration not mentioned)
Number of subjects: 428

Group type: COMPARATOR
Intervention: Nonexposed pregnant women (control group)
Number of subjects: 428
Study: 25939067

Group type: EXPERIMENTAL
Intervention: Riluzole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 25939704

Group type: COMPARATOR
Intervention: Bone geometry, volumetric BMD, and micro-architecture measurements using HR-pQCT
Number of subjects: 18

Group type: COMPARATOR
Intervention: Bone stiffness and strength measurements
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Pro-collagen type 1 N-terminal pro-peptide (P1NP) levels
Number of subjects: 18
Study: 25939720

Group type: EXPERIMENTAL
Intervention: PNPLA3 rs738409 G allele (148Met) presence in overweight/obese with MetS
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: CG and GG genotypes
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Homozygote G allele in individuals aged below 20 years
Number of subjects: 288
Study: 25940115

Group type: EXPERIMENTAL
Intervention: Older women (>35 years)
Number of subjects: 3472

Group type: EXPERIMENTAL
Intervention: Women aged 25-34 years
Number of subjects: 3472

Group type: EXPERIMENTAL
Intervention: Low level of education
Number of subjects: 3472

Group type: EXPERIMENTAL
Intervention: Having >1 life-time sexual partners
Number of subjects: 3472

Group type: EXPERIMENTAL
Intervention: Parity >1
Number of subjects: 3472

Group type: EXPERIMENTAL
Intervention: Being HIV positive
Number of subjects: 3472
Study: 25940342

Group type: EXPERIMENTAL
Intervention: Exercise group
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 160
Study: 25941185

Group type: EXPERIMENTAL
Intervention: Serial biomarker algorithm using a simple blood-based marker (aspartate aminotransferase:ALT ratio for hazardous alcohol users, BARD score for other risk groups) and liver stiffness measurement using transient elastography (TE)
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Non-invasive liver investigation algorithm targeting risk factors
Number of subjects: 504
Study: 25941189

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment applied three times per week for 6 months at 30 minutes per treatment.
Number of subjects: 112
Study: 25941220

Group type: EXPERIMENTAL
Intervention: Cefazolin 1 g
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cefazolin 2 g
Number of subjects: 12
Study: 25942403

Group type: EXPERIMENTAL
Intervention: HTG subjects (with or without statin)
Number of subjects: 15773

Group type: EXPERIMENTAL
Intervention: Subjects on statin
Number of subjects: 15773

Group type: EXPERIMENTAL
Intervention: HTG (with or without statin)
Number of subjects: 15773

Group type: EXPERIMENTAL
Intervention: Triglyceride levels
Number of subjects: 15773

Group type: COMPARATOR
Intervention: Statin treatment
Number of subjects: 15773

Group type: EXPERIMENTAL
Intervention: Triglyceride reduction
Number of subjects: 15773
Study: 25942723

Group type: EXPERIMENTAL
Intervention: Daclatasvir (30 mg), asunaprevir (200 mg), and beclabuvir (75 mg) fixed-dose combination, administered twice daily for 12 weeks.
Number of subjects: 415
Study: 25942724

Group type: EXPERIMENTAL
Intervention: Daclatasvir (30 mg), asunaprevir (200 mg), and beclabuvir (75 mg) with ribavirin (1000-1200 mg/d)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Daclatasvir (30 mg), asunaprevir (200 mg), and beclabuvir (75 mg) without ribavirin
Number of subjects: 202
Study: 25943162

Group type: EXPERIMENTAL
Intervention: Ventricular rate (VR) ≤ 60 bpm (low VR)
Number of subjects: 2821

Group type: EXPERIMENTAL
Intervention: Ventricular rate (VR) ≥ 160 bpm (high VR)
Number of subjects: 2821

Group type: EXPERIMENTAL
Intervention: Electrical cardioversion (ECV)
Number of subjects: 2821

Group type: EXPERIMENTAL
Intervention: Bradycardia
Number of subjects: 2821

Group type: EXPERIMENTAL
Intervention: Thromboembolic complications
Number of subjects: 2821

Group type: EXPERIMENTAL
Intervention: Recurrence of AF
Number of subjects: 2821
Study: 25944344

Group type: EXPERIMENTAL
Intervention: Raltegravir 400 mg twice daily
Number of subjects: 22
Study: 25944628

Group type: EXPERIMENTAL
Intervention: Fasting serum insulin
Number of subjects: 15288

Group type: EXPERIMENTAL
Intervention: HOMA-IR (homeostasis model assessment-insulin resistance)
Number of subjects: 15288

Group type: EXPERIMENTAL
Intervention: Serum-triglyceride-to-serum-high-density lipoprotein-cholesterol ratio (TG/HDL-C)
Number of subjects: 15288

Group type: EXPERIMENTAL
Intervention: Impaired fasting glucose (serum glucose ≥110 mg/dL)
Number of subjects: 15288

Group type: EXPERIMENTAL
Intervention: Insulin
Number of subjects: 15288

Group type: EXPERIMENTAL
Intervention: HOMA-IR
Number of subjects: 15288

Group type: EXPERIMENTAL
Intervention: TG/HDL-C
Number of subjects: 15288

Group type: EXPERIMENTAL
Intervention: Glucose
Number of subjects: 15288
Study: 25944633

Group type: EXPERIMENTAL
Intervention: Full coverage for β-blockers, renin-angiotensin system antagonists, and statins without cost sharing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual coverage for β-blockers, renin-angiotensin system antagonists, and statins at the current level of insurance coverage
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison of full coverage to usual coverage
Number of subjects: 0
Study: 25944758

Group type: EXPERIMENTAL
Intervention: Transcatheter pulmonary valve replacement with the Melody valve
Number of subjects: 171
Study: 25944802

Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan at 12 mg/kg (maximum tolerated dose for cycle 1)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan at 8 and 10 mg/kg
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan
Number of subjects: 25
Study: 25944944

Group type: EXPERIMENTAL
Intervention: SootherMask (InspiRx) small mask
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Vortex (Pari) small mask
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: SootherMask (InspiRx) medium mask
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: AeroChamber (Monaghan Medical) medium mask
Number of subjects: 270

Group type: COMPARATOR
Intervention: Various face masks (small and medium)
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: InspiRx masks (small and medium)
Number of subjects: 270
Study: 25945597

Group type: EXPERIMENTAL
Intervention: Adaptive Paced Visual Serial Attention Task (APVSAT) used at least three times per week for four weeks
Number of subjects: 27
Study: 25945924

Group type: EXPERIMENTAL
Intervention: AIDR 3D mild
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: AIDR 3D standard
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: AIDR 3D strong
Number of subjects: 30

Group type: COMPARATOR
Intervention: FBP/QDS
Number of subjects: 30
Study: 25946437

Group type: EXPERIMENTAL
Intervention: SAPIEN XT transcatheter heart valve
Number of subjects: 2688
Study: 25947565

Group type: EXPERIMENTAL
Intervention: Dinaciclib (escalating doses on day 1) + Epirubicin (standard dose on day 2)
Number of subjects: 9
Study: 25947955

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 25948541

Group type: EXPERIMENTAL
Intervention: Approved clinical decision values (CDVs) for hs-cTn assays (hs-cTnI, Abbott; hs-cTnT, Roche)
Number of subjects: 2300

Group type: EXPERIMENTAL
Intervention: Sex-specific CDVs
Number of subjects: 2300

Group type: EXPERIMENTAL
Intervention: Biologically equivalent CDV
Number of subjects: 2300

Group type: EXPERIMENTAL
Intervention: hs-cTn assays with nearly biologically equivalent CDVs
Number of subjects: 2300

Group type: EXPERIMENTAL
Intervention: Patients with inconsistent AMI diagnoses
Number of subjects: 2300
Study: 25948542

Group type: EXPERIMENTAL
Intervention: More sensitive cardiac troponin (cTn) assays (3 sensitive and 4 high-sensitivity cTn assays)
Number of subjects: 447

Group type: EXPERIMENTAL
Intervention: Optimal receiver-operator characteristic curve-derived cTn cutoff levels
Number of subjects: 447
Study: 25948664

Group type: EXPERIMENTAL
Intervention: Higher usual alcohol consumption (10-g increment)
Number of subjects: 843

Group type: EXPERIMENTAL
Intervention: Higher usual alcohol consumption (10-g increment) compared to co-twin
Number of subjects: 843

Group type: EXPERIMENTAL
Intervention: All beverage types (beer, wine, spirits)
Number of subjects: 843
Study: 25948673

Group type: EXPERIMENTAL
Intervention: Serum retinoic acid (RA) concentration in patients with NAFLD (1.42 ± 0.47 ng/mL)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Serum retinoic acid (RA) concentration in patients with NASH (1.14 ± 0.26 ng/mL)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Serum RA concentrations in control subjects with normal glucose tolerance (2.87 ± 0.52 ng/mL)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Serum RA concentrations in NAFLD patients with normal glucose tolerance (1.61 ± 0.37 ng/mL)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Serum RA concentrations in NASH patients with normal glucose tolerance (1.35 ± 0.34 ng/mL)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: RXRα mRNA expression in liver tissue
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Serum RA concentrations
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: RXRα mRNA levels
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: RXRα protein concentration in patients with NAFLD
Number of subjects: 124
Study: 25948783

Group type: EXPERIMENTAL
Intervention: Healthy Lifestyle Score (HLS)
Number of subjects: 787

Group type: EXPERIMENTAL
Intervention: Social support and network component of HLS
Number of subjects: 787

Group type: COMPARATOR
Intervention: Individual lifestyle components
Number of subjects: 787
Study: 25948786

Group type: EXPERIMENTAL
Intervention: Maternal macronutrient intake (energy, protein, fat, carbohydrates)
Number of subjects: 835

Group type: EXPERIMENTAL
Intervention: Higher carbohydrate intake
Number of subjects: 835

Group type: EXPERIMENTAL
Intervention: Higher fat intake
Number of subjects: 835

Group type: EXPERIMENTAL
Intervention: Lower protein intake
Number of subjects: 835
Study: 25950507

Group type: EXPERIMENTAL
Intervention: Automated Adaptive Servoventilation (ASV)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 27
Study: 25950694

Group type: EXPERIMENTAL
Intervention: Revascularization
Number of subjects: 251

Group type: COMPARATOR
Intervention: Reference (unchanged lifestyle)
Number of subjects: 251
Study: 25951716

Group type: EXPERIMENTAL
Intervention: DHEA supplementation (30 mg, 3 times a day, orally for 3 months)
Number of subjects: 10
Study: 25952086

Group type: EXPERIMENTAL
Intervention: EUS-directed transgastric ERCP (EDGE) using a lumen-apposing metal stent (LAMS)
Number of subjects: 5
Study: 25952091

Group type: EXPERIMENTAL
Intervention: Recurrent CBDS group (n=32)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (n=32)
Number of subjects: 64
Study: 25952707

Group type: EXPERIMENTAL
Intervention: Self-reported STI history among sexually active youth
Number of subjects: 4389

Group type: EXPERIMENTAL
Intervention: Demographic and behavioral correlates of STI history
Number of subjects: 4389

Group type: EXPERIMENTAL
Intervention: Comparison of STI history between genders
Number of subjects: 4389
Study: 25952795

Group type: EXPERIMENTAL
Intervention: Sym004 (12 mg/kg weekly infusions)
Number of subjects: 26
Study: 25952796

Group type: EXPERIMENTAL
Intervention: Sandwich-like neoadjuvant therapy with bevacizumab (induction therapy with bevacizumab and FOLFOX, concurrent chemoradiotherapy with bevacizumab and consolidation chemotherapy with FOLFOX)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Sandwich-like neoadjuvant therapy with bevacizumab
Number of subjects: 25
Study: 25953016

Group type: EXPERIMENTAL
Intervention: ACUSEAL graft (early-cannulation AVG)
Number of subjects: 138
Study: 25953374

Group type: EXPERIMENTAL
Intervention: Capillary Index Score (CIS) favorable (fCIS=2 or 3) with good revascularization (modified thrombolysis in cerebral infarction score 2b or 3)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Capillary Index Score (CIS) poor (pCIS=0 or 1) with good revascularization (modified thrombolysis in cerebral infarction score 2b or 3)
Number of subjects: 78
Study: 25953601

Group type: EXPERIMENTAL
Intervention: Maternal distraction during bottle-feeding
Number of subjects: 28

Group type: COMPARATOR
Intervention: Not distracted mothers
Number of subjects: 28
Study: 25953829

Group type: EXPERIMENTAL
Intervention: MODY3
Number of subjects: 30

Group type: COMPARATOR
Intervention: CTRLs
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: MODY2
Number of subjects: 30
Study: 25954318

Group type: EXPERIMENTAL
Intervention: Maca root (3.0 g/day)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 25954817

Group type: EXPERIMENTAL
Intervention: Home-based educational intervention led by Community Health Representatives (CHRs) including a one hour group didactic session and monthly home-based educational interventions for 6 months.
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Home-based educational intervention led by Community Health Representatives (CHRs) for 6 months.
Number of subjects: 60
Study: 25955252

Group type: EXPERIMENTAL
Intervention: Computer navigation TKA
Number of subjects: 87

Group type: COMPARATOR
Intervention: Conventional TKA
Number of subjects: 87
Study: 25955319

Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 0
Study: 25955359

Group type: EXPERIMENTAL
Intervention: Sutureless amniotic membrane transplantation using AmnioClip
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: AmnioClip application
Number of subjects: 7
Study: 25955404

Group type: EXPERIMENTAL
Intervention: Total Sleep Deprivation (TSD)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Partial Sleep Deprivation (PSD)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Well-rested state
Number of subjects: 11
Study: 25955492

Group type: EXPERIMENTAL
Intervention: Chemotherapeutic and targeted agents
Number of subjects: 23
Study: 25956314

Group type: EXPERIMENTAL
Intervention: Epinephrine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 25956795

Group type: EXPERIMENTAL
Intervention: Pazopanib 800 mg orally once per day and depot octreotide at preprotocol dosage
Number of subjects: 52
Study: 25956918

Group type: EXPERIMENTAL
Intervention: Nifedipine GITS (30, 60 or 90 mg) in combination with another antihypertensive agent
Number of subjects: 4497
Study: 25957377

Group type: EXPERIMENTAL
Intervention: Ranibizumab (Lucentis)
Number of subjects: 31
Study: 25957391

Group type: EXPERIMENTAL
Intervention: modified CODOX-M/IVAC-rituximab regimen
Number of subjects: 34
Study: 25957497

Group type: EXPERIMENTAL
Intervention: α-1-Acid glycoprotein (AGP)
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: AGP, SOFA scores, and SOFA + AGP
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: AGP, SOFA, Acute Physiology and Chronic Health Evaluation II, length of ICU stay
Number of subjects: 277
Study: 25957999

Group type: EXPERIMENTAL
Intervention: AZD3965 (inhibitor of MCT1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control cell lines (K562 for MCT1 and MDAMB231 for MCT4)
Number of subjects: 0
Study: 25958200

Group type: EXPERIMENTAL
Intervention: Peer-driven intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Venue-based sampling
Number of subjects: 0

Group type: COMPARATOR
Intervention: Respondent-driven sampling (RDS)
Number of subjects: 0
Study: 25958314

Group type: EXPERIMENTAL
Intervention: H3-L6 intervention (increased omega-3 fatty acids, reduced omega-6 linoleic acid)
Number of subjects: 55
Study: 25959555

Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 22

Group type: COMPARATOR
Intervention: Lean controls
Number of subjects: 22
Study: 25960972

Group type: EXPERIMENTAL
Intervention: Short-course IV antibiotic treatment (ceftriaxone and metronidazole) for up to 5 days followed by 5 days of oral antibiotics
Number of subjects: 256

Group type: COMPARATOR
Intervention: Long-course IV antibiotic treatment (between days 5 and 10)
Number of subjects: 256
Study: 25961446

Group type: EXPERIMENTAL
Intervention: Dexcom G4 Platinum CGM system (software 505) with hypoglycemic alert set at 80 mg/dL
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dexcom G4 Platinum CGM system (software 505)
Number of subjects: 0
Study: 25961903

Group type: EXPERIMENTAL
Intervention: Intervention to reduce distress in mothers of preterm infants
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Dysfunctional coping style, high depression, anxiety, or trauma symptoms, and low social support
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Maternal response to trauma
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Dysfunctional coping style
Number of subjects: 105
Study: 25962426

Group type: EXPERIMENTAL
Intervention: Temsirolimus 25 mg weekly in a 3-week cycle (MTD determined in Phase I)
Number of subjects: 55
Study: 25962439

Group type: EXPERIMENTAL
Intervention: IPTp-SP (sulphadoxine-pyrimethamine)
Number of subjects: 245
Study: 25962554

Group type: EXPERIMENTAL
Intervention: Levodopa-carbidopa intestinal gel (LCIG) via nasojejunal (NJ) tube and then switched to percutaneous endoscopic gastrojejunostomy (PEG-J) tube in open-label study
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Levodopa-carbidopa intestinal gel (LCIG) replacing daytime oral levodopa-carbidopa in double-blind trial
Number of subjects: 391

Group type: COMPARATOR
Intervention: Nasojejunal (NJ) treatment in open-label study
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: PEG-J weeks 1-4 in open-label/monotherapy trial
Number of subjects: 391

Group type: COMPARATOR
Intervention: PEG-J weeks 1-4 in double-blind/polypharmacy trial
Number of subjects: 391
Study: 25962717

Group type: EXPERIMENTAL
Intervention: Sym004 (9 and 12 mg/kg weekly)
Number of subjects: 39
Study: 25962728

Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MedDiet) for 4 weeks
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MedDiet) for men with elevated baseline hs-CRP (≥2 mg/l)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MedDiet) for men with lower baseline hs-CRP
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MedDiet) for women
Number of subjects: 62
Study: 25963019

Group type: EXPERIMENTAL
Intervention: Panitumumab
Number of subjects: 33
Study: 25963185

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Subjects with myofascial pelvic pain
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Subjects with interstitial cystitis/bladder pain syndrome
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Subjects with interstitial cystitis/bladder pain syndrome plus myofascial pelvic pain
Number of subjects: 105
Study: 25963190

Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 728

Group type: EXPERIMENTAL
Intervention: Salvage lymph node dissection
Number of subjects: 728

Group type: EXPERIMENTAL
Intervention: Combination of radiotherapy and salvage lymph node dissection
Number of subjects: 728

Group type: EXPERIMENTAL
Intervention: Adjuvant hormone therapy
Number of subjects: 728

Group type: EXPERIMENTAL
Intervention: Early hormone therapy as the only salvage treatment
Number of subjects: 728

Group type: EXPERIMENTAL
Intervention: Overall findings from clinical series
Number of subjects: 728
Study: 25963299

Group type: EXPERIMENTAL
Intervention: Fanconi anemia (FA)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Dyskeratosis congenita (DC)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Diamond-Blackfan anemia (DBA) and Shwachman-Diamond syndrome (SDS)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Severe bone marrow failure (BMF)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Overall immune function
Number of subjects: 118
Study: 25963722

Group type: EXPERIMENTAL
Intervention: BGG492 50 mg
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: BGG492 100 mg
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: BGG492 15 mg
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: BGG492 (all doses)
Number of subjects: 13
Study: 25963988

Group type: EXPERIMENTAL
Intervention: Micafungin 100 mg intravenous once daily
Number of subjects: 20
Study: 25964244

Group type: EXPERIMENTAL
Intervention: AZD1775, 225 mg orally twice per day over 2.5 days per week for 2 weeks per 21-day cycle
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: AZD1775
Number of subjects: 25
Study: 25964250

Group type: EXPERIMENTAL
Intervention: Adjuvant regimen of gemcitabine (1,000 mg/m(2) intravenously on days 1 and 8) and capecitabine (1,500 mg/m(2) per day on days 1 to 14) followed by concurrent capecitabine (1,330 mg/m(2) per day) and radiotherapy (45 Gy to regional lymphatics; 54 to 59.4 Gy to tumor bed)
Number of subjects: 79
Study: 25964296

Group type: EXPERIMENTAL
Intervention: Ofatumumab (10 μg/mL)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ofatumumab (10 mg/kg/dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rituximab (10 mg/kg/dose)
Number of subjects: 0
Study: 25964395

Group type: EXPERIMENTAL
Intervention: Caloric restriction (50% reduction) for 6 weeks
Number of subjects: 0
Study: 25964505

Group type: EXPERIMENTAL
Intervention: Methylphenidate (8-week open-label trial)
Number of subjects: 83
Study: 25964591

Group type: EXPERIMENTAL
Intervention: Primary Debulking Surgery (PDS)
Number of subjects: 573

Group type: COMPARATOR
Intervention: Interval Debulking Surgery (I-IDS)
Number of subjects: 573

Group type: COMPARATOR
Intervention: Referred-Interval Debulking Surgery (R-IDS)
Number of subjects: 573
Study: 25964599

Group type: EXPERIMENTAL
Intervention: Decitabine
Number of subjects: 58
Study: 25964643

Group type: EXPERIMENTAL
Intervention: Contemporary radiation therapy in combined modality therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Omission of radiation
Number of subjects: 0
Study: 25965712

Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnea (OSA)
Number of subjects: 10132

Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP) treatment for OSA
Number of subjects: 10132
Study: 25966740

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept (2 mg) injection every 28 days for three consecutive months followed by a fourth injection 8 weeks later.
Number of subjects: 16